The early appearance of exosomal CSF tau in AD argues strongly in favor of CSF-tau biogenesis by active secretion rather than passive postmortem release, since it occurs at a stage (Braak Stage 3) when neurofibrillary degeneration is restricted to a small proportion of the brain (199). This evidence concerns the gene MAPT and Alzheimer disease.